DrugBiological
Amubarvimab clinical trials
Also written BRII-196.
- studies test it
- 7
- open now
- 0
- in phase 3
- 3
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
7 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2020 | 4 |
| 2021 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 3
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Brii Biosciences Limited (3) · Brii Biosciences, Inc. (1)
Often tested with
Tested in the same studies.
Romlusevimab (6) · Bamlanivimab (2) · Cilgavimab and tixagevimab drug combination (2) · Interferon beta-1a (1) · Interferon Beta-1a Inhalation Solution SNG001 (1) · Camostat (1) · Ogalvibart (1) · Crexavibart (1)
Studies
Open first, then newest update. How each study uses amubarvimab is read from its arms, and is right about nine times in ten.
Testing it · 7
- ACTIV-2: A Study for Outpatients With COVID-19CompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT04518410Written as BRII-196+BRII-198
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780424Written as BRII-196
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as BRII-196/BRII-198
- Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196CompletedPhase 1Brii Biosciences LimitedNCT04479631Written as BRII-196
- A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198CompletedPhase 1Brii Biosciences LimitedNCT04691180Written as BRII-196 and BRII-198
- A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198CompletedPhase 2Brii Biosciences LimitedNCT04787211Written as BRII-196 and BRII-198
- A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19WithdrawnPhase 2Brii Biosciences, Inc.NCT04770467Written as BRII-196 and BRII-198
Codes
What other systems call amubarvimab · ClinicalTrials.gg INT001787
- MeSH (NLM) C000721042amubarvimabOne source NLM
- UNII (FDA) 2AD5KH3SE4AMUBARVIMABConfirmed FDA, NLM
- NCI Thesaurus C175227AmubarvimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000721042 | amubarvimab | One source NLM |
| UNII (FDA) | 2AD5KH3SE4 | AMUBARVIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175227 | Amubarvimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.